The collaboration between IIT-Bombay and Lord’s Mark Industries aims to revolutionize sickle cell testing in India, providing improved disease diagnosis and management for patients across the country at the point of primary care, thereby reducing costs and enabling convenience for the affected population.
Mumbai: Lord’s Mark Industries has partnered with the Indian Institute of Technology Bombay (IIT-B) to revolutionise sickle cell testing in India. The first-ever AI-enabled point-of-sale (POS) equipment in the country, patented by IIT Bombay, will address challenges associated with sickle cell testing, making it more accessible and convenient with 100 per cent accuracy. Lord’s Mark Industries will invest Rs 25 crore to develop and distribute the technology-enabled POS equipment, targeting revenue of Rs 100 crore by the year 2026-27.
Lord’s Mark Industries will use its in-house R&D team to manufacture the sickle cell POS instrument at its IVD manufacturing facility in Vasai. The equipment will be available in government healthcare centers, pathology labs, and Lord’s Mark Industries’ pathology labs throughout the country.
Commenting on the collaboration, Sachidanand Upadhyay, Founder, Lord’s Mark Industries said, “Through this collaboration with IIT-B, Lord’s Mark Industries is committed to providing innovative and effective solutions to sickle cell testing across India, especially in rural regions. We are also investing in the establishment of 1000 pathology labs across the country, with an initial investment of Rs 50 crores, to provide easy access to sickle cell testing and other healthcare services. With the support of the central government, we aim to make equipment and testing available across government healthcare centers and hospitals.”
